Leveraging our systematic approach and proven success in recruiting patients for clinical trials, WCG has solved some of the greatest enrollment challenges within the hardest-to-reach patient populations on behalf of our clients. In partnering with WCG, you will dramatically accelerate the enrollment performance of your study. With our enrollment acceleration solution, you can expect predictable success through our unique, deliberate approach to finding the patients you need.
That’s why any attempt to accelerate enrollment using a single strategy is likely to fail. That’s also why WCG’s Enrollment Accelerator Solution uses a holistic strategy, applying proven tools to bring your clinical study’s enrollment up to speed rapidly.
If your trial is facing an enrollment challenge today—or if you want to prevent “unexpected” delays for your next study—now is the time to engage WCG. Our Enrollment Accelerator reduces average enrollment timelines by 33% across all therapeutic indications.
Depending on the causes of your enrollment challenges, WCG applies a combination of efforts precisely targeted to obstacles and sites that are responsible for your enrollment shortfall—achieving an extraordinary record of accelerated enrollment.
WCG matches your study’s qualities against performance data on thousands of clinical sites—thus reducing risk and speeding enrollment.
Our clinical study professionals use intensive, on-site chart review to quickly identify your sites’ full cohort of patient candidates.
Our advanced media and messaging techniques are proven to rapidly and cost-efficiently swell the ranks of qualified patient candidates.
Too many studies fall short after identifying patient candidates: Our driven recruitment specialists ensure you reach target enrollment.
Our advanced educational and electronic informed consent processes better engage patients, increases enrollments, and reduce costs and risk.
WCG’s unmatched Knowledge Base™ of site performance on more than 220,000 investigators in 120 countries ensures you select the most qualified sites to enroll patients for your study.
In addition, no other organization offers our ability to identify and attract qualified patients, then actively recruit them for your study—all in a seamless, integrated effort, faster and at a lower cost than any alternative.
Finally, our eConsent solution ensures that no patients are lost during the sensitive informed consent process. Indeed, our nurturing approach both increases your enrollment rate and fosters increased patient cooperation with your study.
PHASE II DERMATOLOGY STUDY / USA AND EUROPE
Client reaches enrollment goal 24 months earlier than if enrollment would have continued without WCG’s support.
TOP 5 PHARMA STUDY / USA & EUROPE
Enrollment for this 100-patient study had been underway for 10 months across 16 sites globally, yet only 20 patients had been enrolled. WCG patient identification and enrollment acceleration services increased enrollment rate by 5x.
Complete the form to schedule a consultation with WCG. We’ll share benchmark data from the WCG Knowledge Base, analyze your results, and share some of the common practices of top performers.